Cancer-associated autoantibodies as biomarkers for early detection and prognosis is cancer: An update

Current Cancer Therapy Reviews

Volumn 9, Issue 4, 2013, Pages 227-235

  Meistere, Irena ^a   Kalniņa, Zane ^a   Siliņa, Karina ^a   Line, Aija ^a  

^a LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

Author keywords

Autoantibodies; B cells; Biomarkers; Early detection of cancer; Proteomics; Tumor antigens

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G;

AUTOIMMUNE DISEASE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; EARLY DIAGNOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; NEOPLASM; PRIORITY JOURNAL; REVIEW; SEROLOGY; TUMOR MICROENVIRONMENT; VIRUS INFECTION;

EID: 84900795036     PISSN: 15733947     EISSN: 18756301     Source Type: Journal    
DOI: 10.2174/157339470904140418093612     Document Type: Review

References (110)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331(6024): 1565-1570.
2. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92(25): 11810-11813.
3. Mischo A, Wadle A, Watzig K, et al. Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. Cancer Immun 2003; 3: 5.
4. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997; 3(8): 342-349.
5. Preuss KD, Zwick C, Bormann C, Neumann F, Pfreundschuh M. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 2002; 188(1): 43-50.
6. Gnjatic S, Ritter E, Buchler MW, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci USA 2010; 107(11): 5088-5093.
7. Zayakin P, Ancans G, Silina K, et al. Tumor-associated autoanti-body signature for the early detection of gastric cancer. Int J Cancer 2013; 132(1): 137-147.
8. Preiss S, Kammertoens T, Lampert C, Willimsky G, Blankenstein T. Tumor-induced antibodies resemble the response to tissue damage. Int J Cancer 2005; 115(3): 456-462.
9. Ludewig B, Krebs P, Metters H, et al. Molecular characterization of virus-induced autoantibody responses. J Exp Med 2004; 200(5): 637-646.
10. Kalnina Z, Silina K, Line A. Autoantibody profiles as biomarkers for response to therapy and early detection of cancer. Curr Cancer Ther Rev 2008; 4(2): 149-156.
11. Desmetz C, Mange A, Maudelonde T, Solassol J. Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med 2011; 15(10): 2013-2024.
12. Zaenker P, Ziman MR. Serologic autoantibodies as diagnostic cancer biomarkers--a review. Cancer Epidemiol Biomarkers Prev 2013; 22(12): 2161-2181.
13. Somers VA, Brandwijk RJ, Joosten B, et al. A panel of candidate tumor antigens in colorectal cancer revealed by the serological selection of a phage displayed cDNA expression library. J Immunol 2002; 169(5): 2772-2780.
14. Sioud M, Hansen MH. Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries. Eur J Immunol 2001; 31(3): 716-725.
15. Fossa A, Alsoe L, Crameri R, et al. Serological cloning of can-cer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother 2004; 53(5): 431-438.
16. Hansen MH, Ostenstad B, Sioud M. Identification of immunogenic antigens using a phage-displayed cDNA library from an invasive ductal breast carcinoma tumour. Int J Oncol 2001; 19(6): 1303-1309.
17. Zhong L, Peng X, Hidalgo GE, et al. Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics 2004; 4(4): 1216-1225.
18. Minenkova O, Pucci A, Pavoni E, et al. Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients. Int J Cancer 2003; 106(4): 534-544.
19. Pavoni E, Vaccaro P, Pucci A, et al. Identification of a panel of tumor-associated antigens from breast carcinoma cell lines, solid tumors and testis cDNA libraries displayed on lambda phage. BMC Cancer 2004; 4: 78.
20. Lichtenfels R, Kellner R, Atkins D, et al. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochem Biophys Acta 2003; 1646(1-2): 21-31.
21. Klade CS, Voss T, Krystek E, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Pro-teomics 2001; 1(7): 890-898.
22. Hardouin J, Lasserre JP, Canelle L, et al. Usefulness of autoanti-gens depletion to detect autoantibody signatures by multiple affinity protein profiling. J Sep Sci 2007; 30(3): 352-358.
23. Philip R, Murthy S, Krakover J, et al. Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential ther-anostic approach to cancer. J Proteome Res 2007; 6(7): 2509-2517.
24. Hardouin J, Lasserre JP, Sylvius L, Joubert-Caron R, Caron M. Cancer immunomics: from serological proteome analysis to multiple affinity protein profiling. Ann N Y Acad Sci 2007; 1107: 223-230.
25. Grandjean M, Sermeus A, Branders S, et al. Hypoxia integration in the serological proteome analysis unmasks tumor antigens and fosters the identification of anti-phospho-eEF2 antibodies as potential cancer biomarkers. PLoS One 2013; 8(10): e76508.
26. Grandjean M, Dieu M, Raes M, Feron O. A new method combining sequential immunoaffinity depletion and differential in gel elec-trophoresis to identify autoantibodies as cancer biomarkers. J Immunol Methods 2013; 396(1-2): 23-32.
27. Chatterjee M, Mohapatra S, Ionan A, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006; 66(2): 1181-1190.
28. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353(12): 1224-1235.
29. Gnjatic S, Wheeler C, Ebner M, et al. Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J Immunol Methods 2009; 341(1-2): 50-58.
30. Chao T, Ladd JJ, Qiu J, et al. Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy. Proteomics Clin Appl 2013; 7(5-6): 327-336.
31. Anderson KS, Sibani S, Wallstrom G, et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 2011; 10(1): 85-96.
32. Farlow EC, Patel K, Basu S, et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res 2010; 16(13): 3452-3462.
33. Patel K, Farlow EC, Kim AW, et al. Enhancement of a multiana-lyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomark-ers. Int J Cancer 2011; 129(1): 133-142.
34. Ostendorff HP, Awad A, Braunschweiger KI, et al. Multiplexed VeraCode bead-based serological immunoassay for colorectal cancer. J Immunol Methods 2013; 400-401: 58-69.
35. Burbelo PD, Ching KH, Bren KE, Iadarola MJ. Searching for bio-markers: humoral response profiling with luciferase immunopre-cipitation systems. Expert Rev Proteomics 2011; 8(3): 309-316.
36. Burbelo PD, Bren KE, Ching KH, et al. LIPS arrays for simultaneous detection of antibodies against partial and whole proteomes of HCV, HIV and EBV. Mol Biosyst 2011; 7(5): 1453-1462.
37. Zhong L, Coe SP, Stromberg AJ, et al. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Tho-rac Oncol 2006; 1(6): 513-519.
38. Zhong L, Hidalgo GE, Stromberg AJ, et al. Using protein microar-ray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med 2005; 172(10): 1308-1314.
39. Healey GF, Lam S, Boyle P, et al. Signal stratification of autoanti-body levels in serum samples and its application to the early detection of lung cancer. J Thorac Dis 2013; 5(5): 618-625.
40. Kalnina Z, Silina K, Meistere I, et al. Evaluation of T7 and lambda phage display systems for survey of autoantibody profiles in cancer patients. J Immunol Methods 2008; 334(1-2): 37-50.
41. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5(8): 615-625.
42. Hofmann O, Caballero OL, Stevenson BJ, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA 2008; 105(51): 20422-20427.
43. Almeida LG, Sakabe NJ, deOliveira AR, et al. CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res 2009; 37: D816-D819.
44. Shan Q, Lou X, Xiao T, et al. A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. Cancer Lett 2013; 328(1): 160-167.
45. Shimada H, Ochiai T, Nomura F. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiin-stitutional analysis by the Japan p53 Antibody Research Group. Cancer 2003; 97(3): 682-689.
46. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000; 60(7): 1777-1788.
47. Wandall HH, Blixt O, Tarp MA, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 2010; 70(4): 1306-1313.
48. Burford B, Gentry-Maharaj A, Graham R, et al. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. Br J Cancer 2013; 108(10): 2045-2055.
49. Lanzavecchia A, Lezzi G, Viola A. From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell 1999; 96(1): 1-4.
50. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996; 273(5271): 104-106.
51. Watanabe N, Arase H, Onodera M, Ohashi PS, Saito T. The quantity of TCR signal determines positive selection and lineage commitment of T cells. J Immunol 2000; 165(11): 6252-6261.
52. Chang W, Wu L, Cao F, et al. Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma. Clin Cancer Res 2011; 17(17): 5715-5724.
53. O'Rourke DJ, DiJohnson DA, Caiazzo RJ, Jr., et al. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen. Clin Chim Acta 2012; 413(5-6): 561-567.
54. Shi FD, Zhang JY, Liu D, et al. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 2005; 63(3): 252-258.
55. Liu H, Zhang J, Wang S, et al. Screening of autoantibodies as potential biomarkers for hepatocellular carcinoma by using T7 phase display system. Cancer Epidemiol 2012; 36(1): 82-88.
56. Xie C, Kim HJ, Haw JG, et al. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med 2011; 9: 43.
57. Ran Y, Hu H, Zhou Z, et al. Profiling tumor-associated autoanti-bodies for the detection of colon cancer. Clin Cancer Res 2008; 14(9): 2696-2700.
58. Chapman CJ, Healey GF, Murray A, et al. EarlyCDT(R)-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol 2012; 33(5): 1319-1326.
59. Fujiwara S, Wada H, Kawada J, et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer 2013; 108(5): 1119-1125.
60. Nakada T, Noguchi Y, Satoh S, et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun 2003; 3: 10.
61. Barrow C, Browning J, MacGregor D, et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006; 12(3 Pt 1): 764-771.
62. Akcakanat A, Kanda T, Koyama Y, et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 2004; 54(1): 95-100.
63. Li Y, Karjalainen A, Koskinen H, et al. p53 autoantibodies predict subsequent development of cancer. Int J Cancer 2005; 114(1): 157-160.
64. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007; 18(5): 868-873.
65. Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008; 26(31): 5060-5066.
66. Pedersen JW, Gentry-Maharaj A, Fourkala EO, et al. Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer. Br J Cancer 2013; 108(1): 107-114.
67. Barderas R, Villar-Vazquez R, Fernandez-Acenero MJ, et al. Sporadic colon cancer murine models demonstrate the value of autoan-tibody detection for preclinical cancer diagnosis. Sci Rep 2013; 3: 2938.
68. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39(4): 782-795.
69. Richards CH, Flegg KM, Roxburgh CS, et al. The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer. Br J Cancer 2012; 106(12): 2010-2015.
70. Nielsen JS, Nelson BH. Tumor-infiltrating B cells and T cells: Working together to promote patient survival. Oncoimmunology 2012; 1(9): 1623-1625.
71. Nielsen JS, Sahota RA, Milne K, et al. CD20+ tumor-infiltrating lymphocytes have an atypical. Clin Cancer Res 2012; 18(12): 3281-3292.
72. Schmidt M, Hellwig B, Hammad S, et al. A comprehensive analysis of human gene expression profiles identifies stromal immuno-globulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res 2012; 18(9): 2695-2703.
73. Nagalla S, Chou JW, Willingham MC, et al. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol 2013; 14(4): R34.
74. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464(7286): 302-305.
75. Yang C, Lee H, Pal S, et al. B cells promote tumor progression via STAT3 regulated-angiogenesis. PLoS One 2013; 8(5): e64159.
76. Yang C, Lee H, Jove V, et al. Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer. PLoS One 2013; 8(1): e54029.
77. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1(2): 118-129.
78. Berlyn KA, Schultes B, Leveugle B, et al. Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol 2001; 101(3): 276-283.
79. Coughlan S, Harkiss GD, Hopkins J. Enhanced proliferation of CD4+ T cells induced by dendritic cells following antigen uptake in the presence of specific antibody. Vet Immunol Immunopathol 1996; 49(4): 321-330.
80. Nagata Y, Ono S, Matsuo M, et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci USA 2002; 99(16): 10629-10634.
81. Suppiah A, Greenman J. Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer. World J Gastro-enterol 2013; 19(29): 4651-4670.
82. Chang SC, Lin JK, Lin TC, Liang WY. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarci-noma. Int J Oncol 2005; 26(1): 65-75.
83. Von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000; 18(3): 574-583.
84. Hamanaka Y, Suehiro Y, Fukui M, et al. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003; 103(1): 97-100.
85. Kurtenkov O, Klaamas K, Mensdorff-Pouilly S, et al. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 2007; 46(3): 316-323.
86. Hirasawa Y, Kohno N, Yokoyama A, et al. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161(2 Pt 1): 589-594.
87. Budiu RA, Mantia-Smaldone G, Elishaev E, et al. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic bio-markers for platinum-resistant ovarian cancer. Cancer Immunol Immunother 2011; 60(7): 975-984.
88. Von Mensdorff-Pouilly S, Moreno M, Verheijen RH. Natural and Induced Humoral Responses to MUC1. Cancers (Basel) 2011; 3(3): 3073-3103.
89. Bracci PM, Zhou M, Young S, Wiemels J. Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case-control study. Cancer 2012; 118(21): 5384-5394.
90. Pallasch CP, Struss AK, Munnia A, et al. Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibod-ies correlated with prolonged survival. Int J Cancer 2005; 117(3): 456-459.
91. Mange A, Lacombe J, Bascoul-Mollevi C, et al. Serum autoanti-body signature of ductal carcinoma in situ progression to invasive breast cancer. Clin Cancer Res 2012; 18(7): 1992-2000.
92. Chatterjee M, Dyson G, Levin NK, et al. Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence. Cancer Biomark 2012; 11(2-3): 59-73.
93. Nimmerjahn F, Ravetch JV. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 2012; 12: 13.
94. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007; 19(2): 239-245.
95. Karagiannis P, Gilbert AE, Josephs DH, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 2013; 123(4): 1457-1474.
96. Fujimoto M, Yoshizawa A, Sumiyoshi S, et al. Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer. Hum Pathol 2013; 44(8): 1569-1576.
97. Oji Y, Kitamura Y, Kamino E, et al. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor. Int J Cancer 2009; 125(2): 381-387.
98. Chen G, Wang Y, Qiu L, et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J Proteomics 2012; 75(10): 2824-2834.
99. Kodar K, Stadlmann J, Klaamas K, Sergeyev B, Kurtenkov O. Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. Glycoconj J, 2012; 29(1): 57-66.
100. Nesslinger NJ, Sahota RA, Stone B, et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 2007; 13(5): 1493-1502.
101. Hahn S, Nesslinger NJ, Drapala RJ, et al. Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model. Int J Cancer 2009; 125(12): 2871-2878.
102. Jager E, Stockert E, Zidianakis Z, et al. Humoral immune responses of cancer patients against Cancer-Testis antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999; 84(5): 506-510.
103. Yuan J, Adamow M, Ginsberg BA, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A 2011; 108(40): 16723-16728.
104. Zhang JY, Megliorino R, Peng XX, et al. Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol 2007; 46(1): 107-114.
105. Yao Y, Fan Y, Wu J, et al. Potential application of non-small cell lung cancer-associated autoantibodies to early cancer diagnosis. Biochem Biophys Res Commun 2012; 423(3): 613-619.
106. Shan Q, Lou X, Xiao T, et al. A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. Cancer Lett 2013; 328(1): 160-167.
107. Lacombe J, Mange A, Jarlier M, et al. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. Int J Cancer 2013; 132(5): 1105-1113.
108. Zhong L, Ge K, Zu JC, et al. Autoantibodies as potential biomark-ers for breast cancer. Breast Cancer Res 2008; 10(3): R40.
109. Xu YW, Peng YH, Chen B, et al. Autoantibodies as Potential Biomarkers for the Early Detection of Esophageal Squamous Cell Carcinoma. Am J Gastroenterol 2014; 109(1): 36-45.
110. Lin HS, Talwar HS, Tarca AL, et al. Autoantibody approach for serum-based detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2007; 16(11): 2396-2405.